Leidos Holdings just delivered one of the more perplexing post-earnings moves of the season: strong Q1 results, raised full-year guidance, and an 8% single-day sell-off that pushed the stock to a fresh one-year low.
The Q1 beat-and-raise should have been enough to steady sentiment. Instead, the stock fell 7.8% on May 5 to close at $137.19, extending a month-long slide that now totals nearly 14%. The market's verdict appears to reflect concerns beyond the headline numbers — chiefly the well-flagged risk that revenue from Leidos's managed health services business declines, compressing margins in the Health segment even as other divisions perform. That bear case was articulated well before results day and, despite a strong print, has not been dismissed.
Options positioning captured the unease building into the event. The put/call ratio climbed to 0.68 — roughly 1.1 standard deviations above its 20-day average of 0.62 — as investors added downside protection ahead of the release. The reading is well off its 52-week high of 1.40, which tells you the market was not braced for catastrophe, but the drift higher over the past two weeks reflected genuine caution rather than complacency.
Short interest tells a quieter story and should not be mistaken for the cause of the drop. At 2.85% of free float — roughly 3.6 million shares — SI has barely moved, rising just 2.7% on the week and 3% over the past month. Borrow availability is extremely loose, at over 5,000% of short interest, meaning there is no shortage of shares to lend and cost to borrow remains negligible at 0.43%. The ORTEX short score of 34.7 is middling and has barely budged in recent sessions. Short sellers were not orchestrating this decline.
The Street's response was swift but calibrated. Both RBC Capital and Stifel trimmed targets on May 6 — RBC to $180 from $215 (maintaining Outperform), Stifel to $193 from $205 (Hold) — adding to cuts from B of A Securities and Truist Securities in late April. The direction of travel is uniform: every recent action has been a target reduction. Yet crucially, no one has downgraded. The consensus mean target now rests near $195, implying roughly 42% upside to the current price. Whether that gap closes via price recovery or further target reductions is the central question. Wells Fargo, which initiated in April at Equal-Weight with a $165 target, has the most sceptical near-term read among recent entrants, and that $165 level is now only 20% above where the stock trades. On valuation, the trailing P/E has compressed to around 10.9x and EV/EBITDA to 8.6x — both at multi-year lows and down sharply over the past 30 days — making Leidos objectively cheaper than at any point in recent memory, a fact the bulls will lean on.
Institutional holders are large and passive-heavy, with Vanguard (11.9%) and BlackRock (8.2%) the two dominant names. State Street recently added a material 217,000 shares and JP Morgan Asset Management accumulated over 317,000 shares in the quarter, a signal that some active managers were building into the weakness rather than exiting. That said, insider activity in the window prior to the selloff was entirely in one direction: CEO Tom Bell sold ~3,200 shares at $177.89 on March 6, joined by the CFO and multiple division presidents. Those were small in dollar terms relative to the company's $17 billion market cap, and the significance scores assigned to each trade were low. Still, the pattern of broad C-suite selling into the $175-180 range — well above where the stock now trades — is worth noting as context.
The next scheduled earnings date is June 2. Between now and then, the debate runs along a clear fault line: whether the health segment margin headwinds are transitory and already priced into the $137 handle, or whether a prolonged managed-care revenue decline makes the current consensus targets structurally too high. With targets clustered in the $180-$200 range and a stock that has just printed a 52-week low, the magnitude of the gap between price and Street expectations is the number to watch.
See the live data behind this article on ORTEX.
Open LDOS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
